162 related articles for article (PubMed ID: 35707983)
21. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Zhao F; Wang S; Liu L; Wang Y
Int J Clin Pharmacol Ther; 2016 Oct; 54(10):761-70. PubMed ID: 27443665
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis.
Wang Y; Ye Z; Ge L; Siemieniuk RAC; Wang X; Wang Y; Hou L; Ma Z; Agoritsas T; Vandvik PO; Perner A; Møller MH; Guyatt GH; Liu L
BMJ; 2020 Jan; 368():l6744. PubMed ID: 31907166
[TBL] [Abstract][Full Text] [Related]
23. Overview of the safety profile of the H2-receptor antagonists.
Hansten PD
DICP; 1990 Nov; 24(11 Suppl):S38-41. PubMed ID: 1980183
[TBL] [Abstract][Full Text] [Related]
24. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
Reeves JJ; Stables R
Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
[TBL] [Abstract][Full Text] [Related]
25. Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.
He Y; Chan EW; Man KK; Lau WC; Leung WK; Ho LM; Wong IC
Drug Saf; 2014 Sep; 37(9):711-21. PubMed ID: 25096957
[TBL] [Abstract][Full Text] [Related]
26. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
28. A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients.
Aanpreung P; Vanprapar N; Susiva C; Parkpreaw C; Boonyachart C
J Med Assoc Thai; 1998 Mar; 81(3):185-9. PubMed ID: 9623009
[TBL] [Abstract][Full Text] [Related]
29. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
30. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study.
Wu CL; Lei WY; Wang JS; Lin CE; Chen CL; Wen SH
PLoS One; 2020; 15(11):e0242975. PubMed ID: 33253311
[TBL] [Abstract][Full Text] [Related]
31. Association of magnesium sulfate use with mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort study.
Gu WJ; Duan XJ; Liu XZ; Cen Y; Tao LY; Lyu J; Yin HY
Br J Anaesth; 2023 Nov; 131(5):861-870. PubMed ID: 37684164
[TBL] [Abstract][Full Text] [Related]
32. Interaction of ranitidine and famotidine with guinea pig-isolated parietal cells.
Sewing KF; Hannemann H
Pharmacology; 1986; 33(5):274-8. PubMed ID: 2432626
[TBL] [Abstract][Full Text] [Related]
33. Association between the Co-administration of Histamine H
Yamazaki T; Uozumi R; Kawazoe H; Kitazume Y; Iihara H; Fujii H; Takahashi M; Arai T; Murachi Y; Sato Y; Mikami T; Hashiguchi K; Yoshizawa T; Takahashi K; Fujita Y; Hosokawa Y; Morozumi I; Tsuchiya M; Yokoyama A; Hashimoto H; Furukawa T
J Cancer; 2022; 13(10):3073-3083. PubMed ID: 36046656
[No Abstract] [Full Text] [Related]
34. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
35. Proton pump inhibitors versus histamine-2 receptor antagonists for stress ulcer prophylaxis during extracorporeal membrane oxygenation: a propensity score-matched analysis.
Kondo Y; Ohbe H; Matsui H; Fushimi K; Tanaka H; Yasunaga H
BMJ Open; 2020 Sep; 10(9):e037534. PubMed ID: 32994240
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients.
Chen C; Liu H; Duan R; Wang F; Duan L
J Gastroenterol Hepatol; 2021 Aug; 36(8):2131-2140. PubMed ID: 33586808
[TBL] [Abstract][Full Text] [Related]
37. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
38. A pragmatic assessment of proton pump inhibitors vs. histamine type 2 receptor antagonists on clinically important gastrointestinal bleeding and mortality when used for stress ulcer prophylaxis in the ICU.
Boyd C; Hassig T; MacLaren R
Pharmacotherapy; 2021 Oct; 41(10):820-827. PubMed ID: 34478588
[TBL] [Abstract][Full Text] [Related]
39. Association between glucocorticoid use and all-cause mortality in critically ill patients with heart failure: A cohort study based on the MIMIC-III database.
Zhu JL; Hong L; Yuan SQ; Xu XM; Wei JR; Yin HY
Front Pharmacol; 2023; 14():1118551. PubMed ID: 36713831
[No Abstract] [Full Text] [Related]
40. Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells.
Hahm KB; Park IS; Kim HC; Lee KJ; Kim JH; Cho SW; Lee SI
Int J Immunopharmacol; 1996; 18(6-7):393-9. PubMed ID: 9024941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
